Designing phase II trials in cancer: a systematic review and guidance

S R Brown, W M Gregory, C J Twelves, M Buyse, F Collinson, M Parmar, M T Seymour, J M Brown, S R Brown, W M Gregory, C J Twelves, M Buyse, F Collinson, M Parmar, M T Seymour, J M Brown

Abstract

Background: Literature reviews of cancer trials have highlighted the need for better understanding of phase II statistical designs. Understanding the key elements associated with phase II design and knowledge of available statistical designs is necessary to enable appropriate phase II trial design.

Methods: A systematic literature review was performed to identify phase II trial designs applicable to oncology trials. The results of the review were used to create a library of currently available designs, and to develop a structured approach to phase II trial design outlining key points for consideration.

Results: A total of 122 papers describing new or adapted phase II trial designs were obtained. These were categorised into nine levels, reflecting the practicalities of implementation, and form a library of phase II designs. Key design elements were identified by data extraction. Along with detailed description of the key elements and the library of designs, a structured thought process was developed to form a guidance document for choice of phase II oncology trial design.

Conclusion: The guidance offers researchers a structured and systematic approach to identifying phase II trial designs, highlighting key issues to be considered by both clinicians and statisticians and encouraging an interactive approach to more informed trial design.

Figures

Figure 1
Figure 1
Phases of drug development.
Figure 2
Figure 2
Search terms to be used in MEDLINE for the systematic literature review of statistical methods for the design of phase II studies in cancer. Key: .mp=title, original title, abstract, name of substance word, subject heading word; $, wildcard; adjn, within n words either side; /, MeSH term all subheadings.
Figure 3
Figure 3
Flow diagram of papers in review.
Figure 4
Figure 4
Flow diagram of phase II trial design thought process.

References

    1. Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866–1872
    1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK (2008) Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 44: 25–29
    1. Brown SR, Gregory WM, Twelves C, Buyse M, Parmar M, Seymour MT, Brown J (2011) A practical guide to facilitate the clinician/statistician interface in designing phase II oncology trials. Unpublished work
    1. Buyse M (2000) Randomized designs for early trials of new cancer treatments—an overview. Drug Inf J 34: 387–396
    1. Collier R (2009) Drug development cost estimates hard to swallow. Can Med Assoc J 180(3): 279–280
    1. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15: 1873–1882
    1. DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25: 209–216
    1. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D (2010) Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 28: 2641–2647
    1. Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99: 1455–1461
    1. Lee JJ, Feng L (2005) Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23: 4450–4457
    1. Machin D, Campbell MJ (2005) Design of Studies for Medical Research. John Wiley & Sons: Chichester
    1. Machin D, Campbell MJ, Tan S-B, Tan S-H (2009) Sample Size Tables for Clinical Studies. Wiley-Blackwell: Chichester
    1. Mariani L, Marubini E (1996) Design and analysis of phase II cancer trials: A review of statistical methods and guidelines for medical researchers. Int Stat Rev 64: 61–88
    1. Mariani L, Marubini E (2000) Content and quality of currently published phase II cancer trials. J Clin Oncol 18: 429.
    1. McShane LM, Hunsberger S, Adjei AA (2009) Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15: 1898–1905
    1. Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, Di Lorenzo G, Lombardi AV, Signoriello G, Gallo C (2003) Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 4: 305–311
    1. Redman M, Crowley J (2007) Small randomized trials. J Thorac Oncol 2: 1–2
    1. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D (2009) Randomized phase II designs. Clin Cancer Res 15: 1883–1890
    1. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D (2010) The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16: 1764–1769
    1. Stewart DJ (2010) Randomized phase II trials: misleading and unreliable. J Clin Oncol 28: e649–e650
    1. Thezenas S, Duffour J, Culine S, Kramar A (2004) Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer 40: 1244–1249
    1. Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 8: 15–16
    1. Yothers G, Wieand HS, Freireich EJ (2006) Pro/Con: Randomization in phase II clinical trials. Clin Adv Hematol Oncol 4: 776–778

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe